BGPartner has advised Araris Biotech in a CHF 24 million financing round, involving the two co-lead investors 4BIO Capital and Pureos Bioventures.
Araris Biotech, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the proceeds to support advancement of lead ADCs in preclinical and into clinical development.
The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille and the Institute for Follicular Lymphoma Innovation. The round also included participation from existing investors VI Partners, Schroders Capital, btov Partners and Redalpine.
BGPartner has assisted Araris Biotech in the negotiations and advised on all Swiss legal matters regarding this financing round. The team was led by partner Oliver Gnehm (pictured left) and further consisted of senior associate Thomas Gysin (pictured right).